QTTB Q32 Bio Inc.: Rasio rega marang prakiraan pendapatan

Q32 Bio Inc. develops advanced immune regulation methods to combat autoimmune pathologies. The expected P/S ratio provided by the GURU.Markets system reflects capital dynamics, where the current level is 4.90. Transparent resource management ensures the clarity of clinical stages, while a robust team of R&D specialists is retained through stock options, preventing the loss of valuable personnel.

Since Q32 Bio Inc. (QTTB) is in the clinical trial stage and has no commercial sales pending FDA approval, traditional revenue valuation remains speculative. The company's forward P/S trend reflects the ratio of current market capitalization to projected annual sales, allowing investors to promptly track market expectations for future revenues before they are actually confirmed in financial statements.